The 7th China International Import Expo (CIIE) has come to an end, attracting dozens of Fortune 500 original pharmaceutical companies to gather in the medical device and healthcare exhibition area, with over 400 new products being exhibited in China for the first time. Among them, a series of new products representing new quality productivity in the pharmaceutical field under multinational original research drug companies such as Seragon, Roche, Pfizer, etc. have become the highlights of this year's CIIE.
Sinogen: Making longevity within reach
Following the introduction of the advanced oral aging inhibitor, Restorin, by Sinopharm's joint venture subsidiary Sinopharm Sinopharm Sinopharm on a domestic e-commerce platform last year, which sparked the "aging fever", multinational original research drug company Sinopharm has transformed from a "new friend" to a "returning customer". At this year's CIIE, the theme of "Making Longevity within Reach" by Sinogen has brought the latest breakthrough achievements in the field of aging intervention, which has become one of the biggest highlights.
In recent years, aging intervention has been increasingly regarded as the most promising frontier medical field, and related technologies have received much attention. As a global leader in aging intervention technology, Sinogen has launched a groundbreaking new aging intervention product, Rituoling Pro, jointly developed with top medical institutions such as Harvard Medical School and Miaoyou Medical International, in China for the first time at the CIIE, and announced the latest research progress of the largest aging intervention trial to date.
As the technical source of Ruituo Ling Pro, the candidate drug SRN-901 of Sanogen Aging Intervention has extended the remaining lifespan of middle-aged mammals (about 50 years old in humans) by one-third in preclinical trials, and significantly alleviated the decline of body functions such as skin and hair status, motor ability, and cognitive ability caused by age. The incidence of age-related tumors has also been reduced by 40%, reaching the highest level of current aging interventions.
In addition to the Rituoling Pro, Sinogen has also launched its first product in China, ENLIVIEN, jointly developed with Harvard University. According to the China Sleep Big Data Report, the rate of insomnia among adults is up to 38.17%, and more than 513 million people are facing sleep disorders. The mental depression, immune decline, organ damage, and even rapid shortening of life caused by insufficient sleep have become one of the important factors endangering the health of countrymen people. The demand for improving sleep quality and preventing cliff aging is growing day by day.
Thanks to the breakthrough results jointly developed by Sinogen and Harvard University, Rituoling can reduce the lifespan of experimental animals caused by sleep deprivation from 60% to less than 5%, and significantly improve sleep quality by accelerating sleep onset and increasing deep sleep time, achieving efficient recovery through short-term sleep.
Roche: Colorful Thirty, Ju's Future
As a regular visitor to the CIIE and to commemorate its 30th anniversary in China, Roche showcased a comprehensive range of its full product matrix and innovative solutions at the CIIE booth this year under the theme of "Colorful Thirty, Gathering the Future of Roche". Among them, three innovative pharmaceutical products that are about to be approved in China were prominently displayed.
In the future, Roche plans to launch the first PI3K alpha inhibitor Inavolisib, the first CD20/CD3 bispecific antibody innovative drug Lunsumio (Mosunetuzumab) for the treatment of B-cell lymphoma, and the only globally approved drug Ocrevus (Ocrelizumab) for the treatment of both recurrent and progressive multiple sclerosis in China, to meet the health needs of Chinese patients.
Pfizer: Thirty five Chinese emotions surpass yesterday and move towards the future
This year marks Pfizer's 175th anniversary of establishment and 35th anniversary of entry into China. At this year's CIIE, Pfizer presented more than 20 globally leading innovative products and solutions with the theme of "Pfizer's 35 Year China Experience Beyond Yesterday to the Future", including 4 debut products.
This includes Emblaveo, the world's first combination of β - lactam/β - lactam enzyme inhibitors targeting metal β - lactams (MBLs), Talazoparib, a novel dual mechanism PARP inhibitor for prostate cancer, Marscatamab, a hemophilia therapy with a unique mechanism of action, and Elranatamab, a bispecific antibody targeting B cell mature antigen and CD3.
In addition to showcasing its innovative capabilities, Pfizer China's 2030 strategy was also heavily released at this CIIE, demonstrating Pfizer's commitment to continuously cultivating China in the future.